Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs State Street SPDR S&P Biotech ETF — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79, while State Street SPDR S&P Biotech ETF trades at $151.59. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| FLRN | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $30.86 | $164.28 |
52-Week Low | $30.65 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.79 with no price movement in the last 24 hours. The technical picture shows a bearish trend with moving averages indicating selling pressure, though oscillators are neutral. Key financial ratios including P/E, P/S, and ROE are unavailable in the current data. Recent corporate actions include three dividend payments of $0.11 each scheduled for mid-2026, suggesting management's commitment to shareholder returns despite the current technical weakness.
The outlook for FLRN appears cautious with bearish technical signals dominating. The stock faces headwinds from the current market environment where inflation concerns are driving investors toward inflation-protected assets. Investment opportunities exist in the consistent dividend payments, but risks include the overall bearish technical setup and potential pressure from rising interest rates that could impact stock valuations broadly.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
